相关实验视频
Updated: Jul 20, 2025
06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
658
在心力衰竭的小鼠中,达帕格利弗洛辛影响了内皮功能障碍和改变了肠道微生物群
Nandi Bao1, Xiaoli Liu2, Xiaoling Zhong3
1Chinese PLA General Hospital, Beijing, China.
PeerJ
|July 31, 2023
概括
在心力衰竭 (HF) 的小鼠模型中,达帕格利弗洛辛治疗改变了肠道微生物组,减少了有害细菌,丰富了有益的细菌. 这种微生物组调节可能解释了达帕格利弗洛辛在HF患者中的治疗效果.
科学领域:
- 微生物组研究的研究.
- 心血管疾病是什么心血管疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 是一种复杂的疾病,与肠道微生物组失调症有着新兴的联系.
- 了解治疗干预对HF微生物群的影响对于阐明治疗机制至关重要.
研究的目的:
- 在达帕格利弗洛辛治疗期间,对心力衰竭 (HF) 的小鼠模型中调查肠道微生物组概况.
- 为了确定与HF的达帕格利弗洛辛治疗相关的特定微生物变化.
主要方法:
- 构建了一个HF小鼠模型并分析心脏组织.
- 在便样本上进行了16S rDNA测序,用于微生物组分析.
- 利用LEfSe和PICRUSt识别特征肠道微生物群并预测微生物功能.
主要成果:
- 达帕格利弗洛辛治疗减少了心脏炎症,心脏病发作和纤维化,同时改善了内皮依赖扩张.
- 随着达帕格利弗洛辛治疗,Firmicutes/Bacteroidetes的比率下降了.
- 像*Desulfovibrio*,*AF12*和*Paraprevotella*这样的特定属在用达帕格利弗洛辛治疗的HF小鼠中得到了丰富.
结论:
- 观察到的肠道微生物组特征变化可能有助于达帕格利弗洛辛在高血压中产生治疗效果.
- 已识别的标志性肠道微生物种类可以作为生物标志物来区分HF患者和健康个体.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
212
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
212
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:30Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
234
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
234